A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1541-1549

  Han, Cui Yan ^a,b   Yue, Li Ling ^b   Tai, Ling Yu ^a   Zhou, Li ^b   Li, Xue Yan ^b   Xing, Gui Hua ^b   Yang, Xing Gang ^a   Sun, Ming Shuang ^a   Pan, Wei San ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

EGFR; Lung cancer; NLC; Small peptide; Tumor targeting

Indexed keywords

ALANYLGLUTAMYLTYROSYLLEUCYLARGININE; BIOTIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; GLUTAMYLTYROSYLASPARAGYLGLUTAMINE; LEUCYLALANYLARGINYLLEUCYLLEUCYLTHREONINE; LIGAND; LIPID; NANOMATERIAL; PEPTIDE; PROLYLASPARTYLTYROSYLGLUTAMYLGLUTAMYLASPARTIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL ACTIVITY; CELL GROWTH; CELL STRAIN; CELL STRAIN K 562; CELL STRAIN NCI H1299; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NANOPHARMACEUTICS; PEPTIDE LIBRARY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR BINDING; STIMULATION; TUMOR CELL;

EGFR; LUNG CANCER; NLC; SMALL PEPTIDE; TUMOR TARGETING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; HUMANS; IMMUNOHISTOCHEMISTRY; K562 CELLS; LUNG NEOPLASMS; OLIGOPEPTIDES; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84876501963     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S43627     Document Type: Article

References (31)

1. Talekar M, Kendall J, Denny W, Garg S. Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anticancer Drugs. 2011;22(10): 949-962.
2. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded longcirculationg liposomes modified with anti-cancer antibody. J Control Release. 2004;100(1): 135-144.
3. Mamot C, Ritschard R, Küng W, Park JW, Herrmann R, Rochlitz CF. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target. 2006;14(4):215-223.
4. Zhou Y, Drummond DC, Zou H, et al. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007;371(4):934-947.
5. Nechansky A, Kircheis R. Immunogenicity of therapeutics: a matter of efficacy and safety. Expert Opin Drug Discov. 2010;5(11): 1067-1079.
6. Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today. 2011;16(11-12):495-503.
7. Wu X, Zhao R, Li Z, et al. A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2. Biochem Biophys Res Commun. 2004;315(4):1004-1010.
8. Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19(14):1978-1985.
9. Chen Z, Deng J, Zhao Y, Tao T. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. Int J Nanomedicine. 2012;7:3803-3811.
10. Song S, Liu D, Peng J, et al. Novel peptide ligand directs liposomes toward EGFR high-expressing cancer cells in vitro and in vivo. FASEB J. 2009;23(5):1396-1404.
11. Lee GY, Kim JH, Oh GT, Lee BH, Kwon IC, Kim IS. Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. J Control Release. 2011;155(2):211-217.
12. Zhang Y, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials. 2012;33(2):679-691.
13. Hackel PO, Zwick E, Prenzel N, Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol. 1999;11(2):184-189.
14. McCawley LJ, O'Brien P, Hudson LG. Overexpression of the epidermal growth factor receptor contributes to enhanced ligand-mediated motility in keratinocyte cell lines. Endocrinology. 1997;138(1):121-127.
15. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6385):355-365.
16. Song S, Liu D, Peng J, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008;363(1-2):155-161.
17. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature. 1984;311(5985): 483-485.
18. Abe M, Kuroda Y, Hirose M, et al. Inhibition of autophosphorylation of epidermal growthfactor receptor by a small peptide not employing an ATP-competitive mechanism. Biopolymers. 2008;89(1):40-51.
19. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 2011;153(2):141-148.
20. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989;119(2):203-210.
21. Zhang X, Gan Y, Gan L, Nie S, Pan W. PEGylated nanostructured lipid carriers loadedwith 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J Pharm Pharmacol. 2008;60(8):1077-1087.
22. Almiñana N, Polo D, Rodríguez L, Reig F. Biodistribution study of doxorubicin encapsulated in liposomes: influence of peptide coating and lipid composition. Prep Biochem Biotechnol. 2004;34(1):77-96.
23. Askoxylakis V, Garcia-Boy R, Rana S, et al. A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology. PLoS One. 2010;5(12):e15962.
24. Campa MJ, Kuan CT, O'Connor-McCourt MD, Bigner DD, Patz EF Jr. Design of a novel small peptide targeted against a tumor-specific receptor. Biochem Biophys Res Commun. 2000;275(2):631-636.
25. Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm. 2011;8(6):2291-2301.
26. Abe M, Kuroda Y, Hirose M, Watanabe Y, Nakano M, Handa T. Inhibition of autophosphorylation of epidermal growth factor receptor by small peptides in vitro. Br J Pharmacol. 2006;147(4):402-411.
27. Walton GM, Chen WS, Rosenfeld MG, Gill GN. Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J Biol Chem. 1990;265(3): 1750-1754.
28. Levkowitz G, Waterman H, Ettenberg SA, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4(6):1029-1040.
29. Margolis BL, Lax I, Kris R, et al. All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem. 1989;264(18):10667-10671.
30. Liu Z, Duan JH, Song YM, et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med. 2012;10:148.
31. Chen F, Hu Y, Li D, Chen H, Zhang XL. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One. 2009;4(12):e8142.